Business Wire

VOOPOO

2.12.2021 10:37:10 CET | Business Wire | Press release

Share
Honor to Knight! DRAG S/X PnP-X Kit Is Launched

In November, VOOPOO announced the overseas launch of the DRAG S/X PnP-X KIT. The product carries out comprehensive technical upgrading on the basis of DRAG S/X, endows the core concept of "Chivalry" in product design, and pays tribute to the glory and virtue of knights.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211202005381/en/

Originated from the spirit of martial arts of German in the Middle Ages, the spirit of chivalry was then embodied in soldiers of the European battlefield in the 11th century, and guards of emperors and warriors of Christ. Nowadays, chivalry is culturally continued and nobly expressed as gentleman demeanor. Despite passage of time, the only constant is the faith that knight loyally holds and eight virtues of knights flowing in their blood. After learning about this legendary medieval history and digging out the core of chivalry, VOOPOO design and R&D personnel were deeply touched. The four core propositions of " Honor", " Valor", "Justice" and "Spirituality" were included in DRAG S/X PnP-X KIT product for consumers to discover. Every vaping is a fusion of VOOPOO and the connotation of the knight, and every piece of cloud is a spiritual portrait of the knight who rushes to the battlefield heroically.

DRAG S/X PnP-X KIT selects five new knight colors, each of which implies a rich design language. Shield Gold--Knight Templar for Defending Justice. Knight Red--Masked Knight for Pursuit Fairness. Knight Chestnut--Dragon Knight for Defending Glory .Eagle Black--Black Knight for Brave and Fearless. Knight Gray--Paladin for Spirituality.

PnP-X Pod displays knight’s spirituality. The metal materials and knob-filling on the top are upgraded, and the 510 drip tip can be replaced at any time. It is anti-leakage, more convenient, and more flexible. Radiating knight spirituality, PnP-X Pod will give you an enjoyable experience in vaping.

The knight series products bring an "Infinite Airflow System" that supports the adjustment of any airway. More than that, knight symbolizes of bravery and heroism. DRAG S/X PnP-X KIT embodies the knight’s valor spirit. It is equipped with a powerful GENE.TT chip, and adjustable power ranging from 5-60/80w. The product can be started in 0.001 second. The hardware is powerful enough that every knight can charge into the battle, with no worries.

The mission of the knight is to guard the country and territory, glory, and faith, and the beloved princess in their hearts. DRAG S/X PnP-X KIT fitted with 2500 mAh built-in battery and 18650 external battery respectively. The Type-C 5V/2A fast charging interface gives every knight full blood for them to resurrect in an instant. To guard the DRAG S/X PnP-X KIT is to guard the spirit of the knight, the cultural connotation of which has been inherited and innovated for thousands of years.

DRAG S/X PnP-X KIT has been upgraded based on DARG S&DARG X. The biggest highlight is the comprehensive upgrade of the atomizer. For one thing, the PnP X Pod has upgraded the metal decorative ring with knight-style texture. For another, the knob-filling on the top, which is more convenient. Anti-leakage design is more compact, and the 510 drip tip can be replaced at any time. In short, the upgrade of DRAG S/X PnP-X KIT is comprehensive, and is worthy of buying. At the same time, a vaper who likes the appearance of knights can't miss this flagship product with "chivalry spirit." Let us pay tribute to the honor of knights together!

Positioning of DRAG S/X PnP-X KIT and DARG S/X PRO is different. DARG S/X PRO is a top-fitting product for professional vapers who want to experience higher power and bigger cloud.

Founded in 2017, VOOPOO has rapidly grown within a short period of time and is now selling worldwide. VOOPOO is a high-tech enterprise integrating R&D, design, production and brand operations. It has four flagship product series: DRAG, VINCI, ARGUS and V Series. VOOPOO has more than 3000 employees worldwide and its business covers more than 70 countries and regions in North America, Europe and Asia.

WARNING: This product may be used with e-liquid products containing nicotine. Nicotine is an addictive chemical.

For more information, please visit https://www.voopoo.com/ , and follow our IG , Facebook and TikTok pages.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye